Efficacy of vitamin D supplementation on the severity of atopic dermatitis in children: A systematic review and meta-analysis [version 2; peer review: 2 approved]

Afif Nurul Hidayati1,2, Sawitri Sawitri1, Desiana Widityaning Sari1, Cita Rosita Sigit Prakoeswa1, Diah Mira Indramaya1, Damayanti Damayanti1, Iskandar Zulkarnain1, Irmadita Citrashanty1, Yuri Widia1, Sylvia Anggraeni1

1Department of Dermatology and Venereology, Faculty of Medicine, Dr. Soetomo Hospital, Surabaya, East Java, 60132, Indonesia
2Department of Dermatology and Venereology, Universitas Airlangga Hospital, Surabaya, East Java, 60115, Indonesia

Abstract

Background: Atopic Dermatitis (AD) is a common dermatosis in children, that includes skin architecture defects, immune dysregulation, and changes of skin flora. Several new drugs have been found to reduce the severity of AD. Vitamin D is one of the new therapies that is still controversial. The purpose of this research is to conclude the efficacy of vitamin D on atopic dermatitis severity in children aged 0-18 years old.

Methods: A systematic search was conducted on the PubMed, Cochrane, ProQuest, Google Scholar, Clinical Trial website, and university repositories including studies published from January 2010 through October 2020. We compared populations, intervention, study design, and outcomes. Statistical analysis was done with Review Manager 5.4.1.

Results: Eight articles met eligibility and inclusion criteria, four articles provided complete data and were analysed. Not all studies demonstrated the efficacy of vitamin D but a meta-analysis of four studies of vitamin D supplementation vs placebo found a mean difference of -0.93 (95%CI -1.76, to -0.11, p<0.001) of patient outcome, but statistically, there was no difference in cure rate (risk ratio 1.46 (95%CI 0.72, to 2.97, p=0.008) in vitamin D supplementation groups compared to placebo groups.

Conclusions: Vitamin D supplementation in paediatric atopic dermatitis patients could offer improvement of disease severity but the recommended dose and duration of administration cannot be concluded yet.

Keywords
atopic dermatitis, children, efficacy, vitamin D, human health
Corresponding authors: Afif Nurul Hidayati (afif_nurulhidayati@fk.unair.ac.id), Desiana Widtyaning Sari (desiana_ws@yahoo.co.id)

Author roles: Hidayati AN: Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Project Administration, Resources, Supervision, Validation, Writing – Original Draft Preparation, Writing – Review & Editing; Sawitri S: Formal Analysis, Supervision, Validation, Writing – Original Draft Preparation, Writing – Review & Editing; Sari DW: Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Project Administration, Software, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; Prakoeswa CRS: Conceptualization, Investigation, Methodology, Supervision, Validation, Writing – Review & Editing; Indramaya DM: Conceptualization, Formal Analysis, Investigation, Methodology, Project Administration, Software, Validation, Writing – Review & Editing; Damayanti D: Formal Analysis, Investigation, Methodology, Project Administration, Resources, Visualization, Writing – Original Draft Preparation; Zulkarnain I: Conceptualization, Formal Analysis, Investigation, Methodology, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; Citrashanty I: Data Curation, Investigation, Methodology, Resources, Software, Validation, Writing – Original Draft Preparation, Writing – Review & Editing; Widia Y: Conceptualization, Formal Analysis, Investigation, Methodology, Software, Supervision, Validation, Writing – Original Draft Preparation, Writing – Review & Editing; Anggraeni S: Conceptualization, Formal Analysis, Investigation, Methodology, Software, Supervision, Validation, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2023 Hidayati AN et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


First published: 03 Mar 2022, 11:274 https://doi.org/10.12688/f1000research.106957.1
Introduction

Atopic Dermatitis (AD) is now considered a complex multifactorial disease that includes defects in skin barrier structures, immune dysregulation, genetic susceptibility, and changes in skin flora which mostly occur in infancy and childhood. Based on the clinical features, AD can be divided into 3 forms, namely AD in infants (2 months-2 years), children (2–12 years), and adolescents (over 12 years).1 Increasing prevalence of AD has been reported in areas including the Asia-Pacific region, where it is reported that 88% of children with AD have either mild or moderate and 12% have severe AD. However, Indonesia still has a lower prevalence in children between 6-7 years old when compared to Thailand and Malaysia, and a lower prevalence in children aged 13-14 years when compared to Pakistan.2

We found data on the prevalence of pediatric AD patients who had vitamin D insufficiency and deficiency in a study conducted by Wang et al.,3 from 498 pediatric AD patients, 47.8% patients had vitamin D deficiency, 41% patients had vitamin D insufficiency and only 11.2% patients who have normal serum vitamin D levels. It was also found in a study conducted by Farazjadeh et al.,4 that the average serum vitamin D level in pediatric AD patients was lower than controls. Although this study did not describe in detail the prevalence of patients with vitamin D deficiency and vitamin D insufficiency.

In addition to the reduction of skin inflammation, recently, AD treatment has focused more on the regulation of the immune response and enhancing the barrier function of the skin.5 Poor compliance with the use of topical drugs makes some researchers try to find other drugs that are not only safe, cheap, easy to use but also effective. Several recent studies have shown that vitamin D supplementation may be an option, although the results of intervention trials are still conflicting.6

In AD patients, defects in the skin barrier structure, as well as decreased functional integrity and reduced ability to regenerate have roles in inducing immune responses and specific inflammatory reactions.7 In acute lesions, there will be a decrease in AMP (Antimicrobial Peptide) production, an increase in S. aureus colonization, and an effect on the severity of the disease and reduce the risk of infection. Vitamin D can increase barrier function, induce AMP and enhance monocyte and macrophage cell function.8 Vitamin D has been known to have some effects on the innate and adaptive immune systems. Several mechanisms can modulate the progression of AD lesions, such as increasing epidermal differentiation, increasing production of cathelicidin, decreasing Th2 cytokines, decreasing Ig E production, decreasing B cell proliferation, and upregulating of T cells.9

A previous systematic review and meta-analysis in 2019 on vitamin D and AD had reported a highly statistically significant reduction in SCORAD (Scoring of Atopic Dermatitis) on intervention with vitamin D, in the paediatric and adult population.10 While a systematic review published by Huang on the paediatric AD population in 2018 concluded that 67% of the collected studies reported a significant improvement in AD severity with vitamin D supplementation, but this systematic review did not include a meta-analysis.11 We conducted a meta-analysis with research published in last 10 years because there has been an increase in publications regarding vitamin D supplementation during this time.12

The main objective of our systematic review and meta-analysis is to provide an updated review of the interventional study of vitamin D in the paediatric AD population to investigate clinical outcomes from measuring scales.

Methods

Search procedures

We conducted a systematic search of the literature on several databases, namely PubMed, Cochrane Library, ProQuest, and a clinical trial website, ClinicalTrials.gov with keywords showed in Table 1 (see also Extended data55). We also did manual hand searching on Google Scholar and searched for grey literature on the repository (including research from January 1st 2010 to October 31st 2020, and the databases were last searched on 2nd November 2020). The search procedure was based on Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA).
A completed PRISMA checklist is available in Reporting guidelines. This search of titles and abstracts was limited to articles that were human-focused and published in English and Bahasa Indonesia. Statistical analysis was carried out with Review Manager (RevMan, Cochrane, London, UK) version 5.4.1 with standardized mean difference and risk ratio as a measure of the effect of therapy.

In studies that include children and adults as participants, we contacted the author to obtain separate data that contained child subjects only. The ethical clearance of this study has been published from the Ethical Committee of Dr. Soetomo General Academic Hospital Surabaya number 0206/LOE/301.4.2/XI/2020. We did not register the protocol.

Eligibility criteria for inclusion and exclusion

Intervention studies including Randomized Control Trials and Prospective Cohort studies with clinical outcomes measured on a scale in both groups, before and after the intervention were assessed. Inclusion criteria were as follows: (1) studies with age group 0-18 years old and diagnosed as mild, moderate, or severe atopic dermatitis in both females and males; (2) No restriction to the duration of intervention, type of vitamin D, doses used, frequency and route of administration, and clinical outcome measuring scale: SCORAD, EASI (Eczema Area and Severity Index), IGA (Investigator Global Assessment). (3) studies that provided complete data for clinical outcomes. Exclusion criteria were articles that did not provide full text.

Outcomes of the study

1. Evaluating the outcome of the disease (changes in SCORAD or EASI) in the Vitamin D supplementation groups compared to placebo groups.

2. Calculating the clinical importance of both groups so that the CER (Control Event Rate), EER (Experimental Event Rate) and NNT (Number Needed to Treat) values can be obtained.

Data extraction and quality analysis

This analysis included all articles that qualified for selection criteria. Two author, ANH and SS extracted data from each included study including author, country, publication year, study population, AD severity, supplementation dose, frequency, route of administration, duration and outcome scale. The clinical outcome was measured by scale: SCORAD, EASI or IGA. We defined the clinical outcomes as follows:

(1) SCORAD: A clinical measurement tool used to calculate the severity of Atopic Dermatitis patients. The lesion area was calculated based on the rule of nine with a value of 0-100. Intensity was measured in a representative area by looking at the form of skin abnormalities that were erythema, edema, oozing or crusts, excoriations, lichenification, and dry skin, and each was assigned a value of 0 if there was no lesion, 1 if the lesion was mild, and 2 if the lesion was moderate and 3 if the lesion was severe, then the scores were summed to get B (0-18). Subjective symptoms were measured by Visual Analog Scale (VAS), calculated on average for every 3 night whether there were symptoms of itching and sleep disturbances, with a score of 0 if there was no itching or sleep disturbances, and 10 for the most severe itching or sleep disturbances. These numbers
are summed to give C (0-20). The results of the three parameters were submitted into the formula A5+7B/2 +C, then grouped into mild AD (<25), moderate AD(25-50) and severe AD(>50) categories.\textsuperscript{13}

(2) EASI: an instrument used by examiners (doctors, dermatologists) to quantify lesion progression and severity of AD patients, by assessing the extent of the disease at four body sites (head/neck, trunk including genitalia, superior and inferior extremities) and measures four clinical signs: (1) erythema, (2) induration/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3. The score can then be divided into 0 (clean), 0.1-1.0 (nearly clean), 1.1-7 (mild), 7.1-21 (moderate), 21.1-50 (severe), 50.1-72.0 (very severe). EASI confers a maximum score of 72.\textsuperscript{13}

(3) IGA: an instrument used to assess overall disease severity at one given time point, and it consists of a 6-point severity scale from clear to very severe disease (0 = clear, 1 = almost clear, 2 = mild disease, 3 = moderate disease, 4 = severe disease and 5 = very severe disease). IGA uses clinical characteristics of erythema, infiltration, papulation, oozing and crusting as guidelines for the overall severity assessment.\textsuperscript{14}

The covidence quality assessment template was customized for this study and the quality of each study was assessed by three authors (ANH, SS and DWS) independently by using the Centre for Evidence-Based Medicine’s RCT (Randomized Control Trial) worksheet, by conducting a critical appraisal to determine validity, importance and applicability. Validity was assessed based on Recruitment, Allocation and Measurement Blinding Outcome. Importance was assessed based on clinical data as well as statistical data. Applicability was assessed by answering several questions related to the author’s setting (Table 2). Critical appraisal for prospective (cohort) study was conducted using critical appraisal skill programme worksheet (Table 3). Another author resolved any disagreement between them (CRSP, DMI,

<table>
<thead>
<tr>
<th>Table 2. Critical appraisal of included interventional studies in systematic review using Randomized Control Trial (RCT) worksheet.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Recruitment</strong></td>
</tr>
<tr>
<td>Recruitment</td>
</tr>
<tr>
<td>Similarity</td>
</tr>
<tr>
<td>Allocation</td>
</tr>
<tr>
<td>Minimum loss to follow up</td>
</tr>
<tr>
<td>Measurement blinding outcome</td>
</tr>
<tr>
<td>Importance</td>
</tr>
<tr>
<td>Statistical</td>
</tr>
<tr>
<td>Applicability</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Table 3. Critical appraisal of included cohort studies in systematic review.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Filippo, 2015</strong></td>
</tr>
<tr>
<td>Representative of the population</td>
</tr>
<tr>
<td>Methods for exposure objective and consistent</td>
</tr>
<tr>
<td>Subjects/outcome accessor blinded</td>
</tr>
<tr>
<td>Sufficiency of follow up</td>
</tr>
<tr>
<td>Overcoming confounding factor</td>
</tr>
<tr>
<td>Importance</td>
</tr>
<tr>
<td>Applicability</td>
</tr>
</tbody>
</table>
Quality analysis of the interventional studies had showed three studies scoring randomized double-blind clinical trials with adequate randomization and blinding. These were Refs. 15, 16 and 17. The other study did not mention randomization but confirmed the blinding of both participants and researchers. 18

The risk of bias in RCT studies was assessed with The Cochrane Collaboration’s tool for assessing risk of bias 18 by ANH, SS and DWS, then we discussed the outcome until we were in agreement. The assessment results were categorized as “yes” for low-risk bias, “unclear”, and “no” for high-risk bias (Figure 1). Cohort studies was assessed with Newcastle-Ottawa Scale (NOS) 19 and comprised several items including comparability of the groups (2 points), and ascertainment of exposure (3 points). Each study was interpreted to be low quality (scores <4), moderate quality (scores of 5–6), or high quality (scores ≥7) that was shown in Table 4.

Statistical analysis
We performed the data with Review Manager (RevMan, Cochrane, London, UK) version 5.4.1. Three authors, DWS, IC, and SA conducted statistical analysis and presented the result in a forest plot and funnel plot. Statistical analysis was done by calculating the standardized mean differences (SMDs), with 95% CIs, of pre- and post-intervention in both groups, and the standard deviation of each study, and was also calculating risk ratio (RR), with 95% CIs, by counting the number of events in each group with a dichotomy table (Table 5). Significance of RRs was determined using the Z test (p<0.05 was considered

Figure 1. Risk of bias summary: review authors’ judgements about each risk of bias item for each included study.

Table 4. Quality analysis of included studies using Newcastle Ottawa Quality Assessment Form for Cohort Studies.

<table>
<thead>
<tr>
<th>Study</th>
<th>Criterion Score</th>
<th>Comparability</th>
<th>Exposure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Filippo, 2015</td>
<td>★★★</td>
<td>★★</td>
<td>★★</td>
</tr>
<tr>
<td>Raj, 2020</td>
<td>★★★</td>
<td>★★</td>
<td>★★</td>
</tr>
</tbody>
</table>

and DD). Quality analysis of the interventional studies had showed three studies scoring randomized double-blind clinical trials with adequate randomization and blinding. These were Refs. 15, 16 and 17. The other study did not mention randomization but confirmed the blinding of both participants and researchers. 18

The risk of bias in RCT studies was assessed with The Cochrane Collaboration’s tool for assessing risk of bias 18 by ANH, SS and DWS, then we discussed the outcome until we were in agreement. The assessment results were categorized as “yes” for low-risk bias, “unclear”, and “no” for high-risk bias (Figure 1). Cohort studies was assessed with Newcastle-Ottawa Scale (NOS) 19 and comprised several items including comparability of the groups (2 points), and ascertainment of exposure (3 points). Each study was interpreted to be low quality (scores <4), moderate quality (scores of 5–6), or high quality (scores ≥7) that was shown in Table 4.

Statistical analysis
We performed the data with Review Manager (RevMan, Cochrane, London, UK) version 5.4.1. Three authors, DWS, IC, and SA conducted statistical analysis and presented the result in a forest plot and funnel plot. Statistical analysis was done by calculating the standardized mean differences (SMDs), with 95% CIs, of pre- and post-intervention in both groups, and the standard deviation of each study, and was also calculating risk ratio (RR), with 95% CIs, by counting the number of events in each group with a dichotomy table (Table 5). Significance of RRs was determined using the Z test (p<0.05 was considered
statistically significant). We assessed the heterogeneity among the studies using $I^2$ (considered heterogeneity existed if $I^2 > 25\%$), then Random Effect Model was adopted. For publication bias, we used funnel plot and it can be seen that the four studies are distributed symmetrically, that is, the distribution of research is balanced on the left and right of the centre line boundary. This means that there is no potential for publication bias regarding the conclusions.

**Results**

570 articles were initially retrieved, and the results of the evaluation of duplicate articles by title showed 157 articles with similar titles and were subsequently excluded from this study. The next evaluation was carried out by reviewing the title of each piece of literature that had been searched based on keywords. There were 11 literatures by excluding 402 literature that was irrelevant with the study design. We did further evaluation of 11 kinds of literature based on eligibility criteria, critical appraisal, and quality assessment, and excluded two articles with subject included aged $> 18$ years old and one

<table>
<thead>
<tr>
<th>Vitamin D</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Not cure</strong></td>
<td><strong>Cure</strong></td>
</tr>
<tr>
<td>Camargo, 2014 $^{16}$</td>
<td>25</td>
</tr>
<tr>
<td>Sanchez-Armendariz, 2018 $^{17}$</td>
<td>3</td>
</tr>
<tr>
<td>Earlia, 2020 $^{18}$</td>
<td>2</td>
</tr>
</tbody>
</table>

**Figure 2.** PRISMA flow diagram to show results of the search process and inclusions/exclusions.
<table>
<thead>
<tr>
<th>Author</th>
<th>Country</th>
<th>Dose, frequency and duration</th>
<th>Study design</th>
<th>Mean age (years)</th>
<th>Outcome scale</th>
<th>AD severity</th>
<th>Supplementation giving method</th>
<th>Study population</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Camargo et al., 2014</td>
<td>Mongolia</td>
<td>Vitamin D₃ 1000 IU/day for 1 month</td>
<td>RCT</td>
<td>9</td>
<td>EASI</td>
<td>Mild, moderate, severe</td>
<td>orally</td>
<td>Paediatric patients with winter-associated AD, EASI between 10-72, based on randomization with a random number generator.</td>
<td>Vitamin D supplementation showed clinical improvement</td>
</tr>
<tr>
<td>Lara-Corrales et al., 2018</td>
<td>Canada</td>
<td>Vitamin D 2000 IU/day for 3 months</td>
<td>RCT</td>
<td>7.4</td>
<td>SCORAD</td>
<td>Mild, moderate, severe</td>
<td>orally</td>
<td>Paediatric patients with AD, with vitamin D deficiency or insufficiency status</td>
<td>Vitamin D supplementation did not significantly improve severity</td>
</tr>
<tr>
<td>Sanchez-Armendariz et al., 2018</td>
<td>Mexico</td>
<td>Vitamin D₃ 5000 IU/day for 3 months</td>
<td>RCT</td>
<td>12.6</td>
<td>SCORAD</td>
<td>Mild, moderate, severe</td>
<td>orally</td>
<td>Paediatric and adult patients with AD according to the criteria of Hanifin Rajka, which were randomized (simple randomization) with a software.</td>
<td>Vitamin D3 can be considered as adjuvant therapy in AD</td>
</tr>
<tr>
<td>Earlia et al., 2020</td>
<td>Indonesia</td>
<td>Vitamin D 600 IU/day for 1 month</td>
<td>RCT</td>
<td>5</td>
<td>SCORAD</td>
<td>Mild, moderate, severe</td>
<td>orally</td>
<td>Paediatric patients with AD who seek for treatment at the Dermatology Clinic for a certain period</td>
<td>Vitamin D supplementation for 1 month was more effective in reducing the severity of AD in children than standard therapy.</td>
</tr>
</tbody>
</table>

Note: RCT, Randomized Control Trial; EASI, Eczema Area Severity Index; SCORAD, Scoring Atopic Dermatitis; AD, Atopic Dermatitis.
## Table 7. Summary of the included studies.

<table>
<thead>
<tr>
<th>Author</th>
<th>n-(experimental group)</th>
<th>n-(control group)</th>
<th>Mean difference of intervention group (pre and post Vitamin D supplementation); standard deviation</th>
<th>Mean difference of intervention group (pre and post placebo supplementation); standard deviation</th>
<th>Duration</th>
<th>p value</th>
<th>Other outcomes</th>
<th>Adverse effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Camargo et al., 2014[^16]</td>
<td>57</td>
<td>47</td>
<td>-6.5 (8.8)</td>
<td>-3.3 (7.6)</td>
<td>1 month</td>
<td>0.04</td>
<td>IGA Score in the experimental group was smaller than the placebo group</td>
<td>None</td>
</tr>
<tr>
<td>Lara-Corrales et al., 2018[^15]</td>
<td>21</td>
<td>24</td>
<td>-15.35 (9.71)</td>
<td>-15.13 (8.97)</td>
<td>3 months</td>
<td>0.07</td>
<td>Patients with severe AD have low 25(OH) D levels</td>
<td>None</td>
</tr>
<tr>
<td>Sanchez-Armendariz et al., 2018[^17]</td>
<td>19</td>
<td>24</td>
<td>-22.84 (11.43)</td>
<td>-13.45 (11.04)</td>
<td>3 months</td>
<td>0.02</td>
<td>Serum vitamin D levels in all experimental groups reached &gt;30ng/ml at the end of the study</td>
<td>Not reported</td>
</tr>
<tr>
<td>Earlia et al., 2020[^18]</td>
<td>15</td>
<td>15</td>
<td>-16 (6.64)</td>
<td>-3.31 (2.47)</td>
<td>1 month</td>
<td>&lt;0.001</td>
<td>None</td>
<td>Not reported</td>
</tr>
</tbody>
</table>

Note: n, Number of subject; IGA, Investigator Global Assessment; AD, Atopic Dermatitis; 25(OH) D, 25-hydroxy vitamin D.
article with non-AD subjects as a comparison group. Qualitative synthesis then resulted two studies that could not be included in the meta-analysis due the fact that no standard deviation was reported.21,22 A further two studies were also excluded due to the study design which was single-arm cohort23,24 so that the final results were four articles which were then analysed in this study.

Four articles were included in meta-analysis, as described in Figure 2. The years of publication for all studies were ranging from January 2010 to October 2020. Three studies were conducted with paediatric participants only15,16,18 and one study was conducted with adult and paediatric participants.17 There were different doses and durations in supplementing vitamin D among studies. One study reported that vitamin D supplementation did not significantly improve the severity of the disease,15 but the other three studies reported otherwise. This study only included AD participants with deficiency or insufficiency status of serum vitamin D. We summarized all studies including population, sample size, intervention, and mean difference outcome of both groups (Vitamin D and placebo groups). All outcomes listed as positive (p<0.05) or negative (p>0.05) are shown in Table 7.

Effect of vitamin D supplementation in paediatric AD patients

Four randomized controlled trials assessed the efficacy of vitamin D supplementation. The characteristics of the included studies are summarized in Table 6. Three studies measured the SCORAD indexes, whereas only one of the included studies assessed the efficacy of vitamin D supplementation by using EASI. One study used both adults and children as a participant, so we contacted the author to obtain the data associated with the children only. A meta-analysis of four trials showed that the SCORAD index and EASI score decreased significantly after vitamin D supplementation (standardized mean difference = -0.93, 95% CI = -1.76 to -0.11). We observed statistical heterogeneity among the studies (I² > 25%; Figure 3). We also assessed the potency of the publication bias in those included studies with funnel plot and the result was symmetrical indicated that there was no potency of the publication bias in the four included studies.

Risk ratio of vitamin D supplementation group

We used the three studies that provided raw data so that the risk ratio of those studies could be measured. The forest plot (see Underlying data35) showed that statistically, there was no difference risk ratio between vitamin D group and placebo group (risk ratio =1.46, 95% CI = 0.72 to 2.97). We observed statistical heterogeneity among the studies (I² > 25%; Figure 4) so Random Effect Model was adopted.

Discussion

Vitamin D can modulate the innate immune system and also increases the phagocytic ability of immune cells and strengthens the barrier function of epithelial cells.8

An in vitro study reported that cathelicidin and defensin (which are antimicrobial-like peptides) increased after vitamin D supplementation.25 Another clinical trial also demonstrated that cathelicidin production could be increased and LL-37
expression could be induced by vitamin D supplementation. Thus, vitamin D could increase antimicrobial activity and external tolerability against pathogens.  

Vitamin D stimulates the production and regulation of skin antimicrobial peptides, such as cathelicidins which exert direct antimicrobial activity and induce host cellular responses to produce cytokine release, inflammation, and angiogenesis, thus, based on the above theory, vitamin D deficiency may predispose to secondary infection in AD patients.  

This is following what was reported by Haridas, Udompataikul et al. who found a reduction in S. aureus colonization in a paediatric population, as well as Rahmawati et al, who have reported that there was a significant difference in the reduction of S. aureus colonization after vitamin D3 supplementation in children with AD Refs. 28 and 29.

This theory is following the results of the meta-analysis of our forest plot. Our findings showed a statistically significant difference between the vitamin D supplementation group and the placebo group. In our study, we found high heterogeneity and we assumed that it was caused by variation of the doses and duration. The meta-analysis published by Kim in 2016  

reported the same results but for the paediatric and adult population, as well as the meta-analysis reported by Haridas in 2018. To our knowledge, our study is the first one that reported vitamin D supplementation efficacy only in children population with AD as the meta-analysis.

The outcome of cure rate is one of the risk ratio, wherein this study the risk ratio calculated is the comparison of the probability of recovered participant between vitamin D and placebo. In the forest plot with risk ratio output, three squares were obtained, each represented 3 studies, with a weight of 45.4%; 48.6%, and 6%. All of these studies have heterogeneity above 50% and p-value <0.05 so that the forest plot used the Random Effect Model as seen from the heterogeneity test results and with the eyeball test. Diamond, the result of all studies is on the left side, with a pooled result of 1.46 (CI between 0.72 to 2.97) and touched the vertical line, which means that statistically, there was no difference in cure rate in the vitamin D group and the placebo group. Previously, there were no published meta-analysis with a forest plot with risk ratio outcomes so to our knowledge, our finding is the first meta-analysis with the risk ratio outcome, by point of interest “cure rate” in the experimental group compared to placebo.

The limited number of studies, differences in dose and duration of vitamin D supplementation, differences in race and geographic conditions, dietary variation, sun exposure, as well as differences in measurement variables after vitamin D supplementation administration could be factors that influenced the risk ratio of cure rate, so we expect that more similar studies can be carried out in 1 country thereby reducing the heterogeneity of each study.

In this study, the clinical significance could only be calculated from 3 studies that provided data on the proportion of subjects who recovered and did not recover or had persistent symptoms from the start of the study to the end. As a determination of the criteria for recovery, we had referred to a journal that mentioned MCID (Minimal Clinically Important Difference) in AD, MCID could be described as a clinical improvement that significantly along with reduction of SCORAD of 9 points and EASI by 6 points and IGA score reduced by 1 point.  

From Table 5, Figure 1 it can be calculated that the CER or incidence in the control group (placebo) was 38/86, which is 44%, means that 44% of cases were cured in the group of subjects who were given placebo and EER or the incidence in the experimental group was 61/91, which is equal to 67%, which means that 67% of cases of cure were found in the vitamin D group. ARR (Absolute risk reduction) in both groups was enabled by reducing CER and EER by 23%, and NNT (number needed to treat) was the amount subjects who must be treated at one time to prevent 1 adverse outcome. In these studies, NNT = 4.34 or required 5 subjects to be treated to prevent 1 unwanted event.

From the literature we obtained, only 1 study used 2 phases in the flow of participant/subject selection. This study measured serum vitamin D levels in pediatric AD patients, and only AD patients with insufficiency and deficiency status were included, thereby reducing the possibility of heterogeneity in experimental group and control group characters.  

Another study measured the vitamin D levels of all subjects in both the placebo group and the experimental group, and found that 100% of patients given vitamin D3 supplements reached sufficient levels at the end of the study.  

Two other studies did not measure vitamin D levels in subjects either before or after administration of vitamin D3 supplements, and these two studies used doses that tended to be lower than other studies, and the duration of administration was relatively shorter.  

What is interesting is that the study conducted by Corrales actually showed that vitamin D supplementation did not provide significant clinical improvements in pediatric AD patients.  

In our opinion, the patient's vitamin D3 status at the beginning of the study might be an influencing factor in the patient's clinical improvement. Apart from that, the doses and duration of administration would also have an influence in giving improvement in AD patients.

If toxicity occurs, there will be an increase in 25(OH) D levels which can trigger hypercalcemia by increasing calcium absorption and bone resorption. Hypercalcemia can lead to hypercalciuria, and persistently elevated calcium levels can
lead to polyuria and dehydration. Vitamin D toxicity is caused by hypercalcemia, which is described by the appearance of symptoms in several organs that can be involved, such as the central nervous system (lethargy, apathy, depression to coma), heart and blood vessels (hypertension, heart rhythm disturbances), gastrointestinal (vomiting), recurrent abdominal pain, anorexia, constipation, and weight loss), and kidney (hypercalciuria is an early symptom, polyuria, polydipsia, nephrocalcinosis, up to life-threatening symptoms such as dehydration and kidney failure requiring haemodialysis). The diagnosis of vitamin D toxicity was established based on a detailed examination and history of taking medication, as well as supporting examinations. Laboratory tests show suppression of parathyroid hormone, which results in increased levels of 1,25(OH)2D.

Limitations
Dose and duration among studies are not similar, and not all studies have observed vitamin D levels before and after supplementation so it has not been seen whether there is an increase in vitamin D levels that exceeds the limit, which could potentially cause signs of vitamin D toxicity in several organs.

The limitation of our study was that we did not perform sub-group analysis outcome according to the measuring scale and the severity of AD due to the limitations of the studies included, so that the result of our study should be used carefully.

Suggestions
Further trials with vitamin D3 with the same dose and duration, followed by observation of serum vitamin D levels as an evaluation of the occurrence of side effects.

Conclusions
Our study has showed that statistically, vitamin D supplementation can improve the outcome of atopic dermatitis in children as assessed by SCORAD, EASI or IGA Score and clinically, vitamin D supplementation can increase the cure rate in AD patients. Observation of side effects and monitoring of 25(OH) D levels in AD patients are required as the toxicity can lead into morbidity. The recommendation of the proper dose of vitamin D supplementation cannot be determined yet because there were no studies with the same dose and duration of administration of the vitamin D supplementation.

Data availability
Underlying data

This project contains the following underlying data:
- Data untuk forest plot.xlsx (data underlying forest plot).

Extended data

This project contains the following extended data:
- Cochrane.jpeg (Cochrane search strategy).
- PubMed.jpeg (PubMed search strategy).
- ProQuest.jpeg (ProQuest search strategy).
- PRISMA flowchart.pdf

Reporting guidelines

Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0).
**Acknowledgments**

Authors wish to thank Dra. Judith Dominguez Cherit, Irene Lara-Corrales, MD, MSc and Dr. Nanda Earlia, Sp.KK for their support in completing our study.

**References**


Open Peer Review

Current Peer Review Status: ✔ ✔

Version 2

Reviewer Report 10 October 2023

https://doi.org/10.5256/f1000research.155801.r209122

© 2023 Budianti W. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

✔ Windy Keumala Budianti

Department of Dermatology and Venereology, Faculty of Medicine, dr. Cipto Mangunkusumo General Hospital, Universitas Indonesia, Jakarta, Indonesia

Dear editor,

I have reviewed the new revisions made by the authors and it is appropriate with the questions that I asked. I want to update my status of the submission to "Approved".

Regards,
Windy Keumala Budianti

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Dermatology and Venereology, Allergy and Immunology, Dermatosis occupational.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Version 1

Reviewer Report 24 May 2023

https://doi.org/10.5256/f1000research.117964.r126212

© 2023 Budianti W. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Vitamin D is a therapy that is often used in several inflammatory skin diseases because it has an immunomodulatory effect. One of the diseases is atopic dermatitis (AD), which in children is a problem that is often faced by dermatologists. The cause of AD is based on the disruption of the skin barrier and impaired regulation of the immune response. However, there are still few evidence-based studies on the benefits or efficacy of vitamin D. The authors attempted to conduct a systematic review and meta-analysis with the aim of studying the effectiveness of vitamin D in pediatric atopic dermatitis using several validated measures, such as SCORAD, EASI, and IGA.

I appreciate the work the authors have done, but there are a few things that might be added to this article.

1. At the introduction, the prevalence of AD in children was presented, it might be better if data were added on the prevalence of vitamin D deficiency or insufficiency in atopic dermatitis in children, which is a risk factor for AD.

2. The method used starts from a literature search, determining eligible criteria for inclusion and exclusion, data extraction and quality analysis, and statistical analysis using Revman version 5.4.1. is already good and clearly visible on the PRISMA flow chart.

3. As for the results, the data for the duration, dose and improvement of AD on vitamin D administration from the literature varied. The study of Earlia et al. showed that with vitamin D supplementation at a dose of 600 IU / day for 1 month of administration showed significant improvement compared to standard therapy alone. In contrast, the Lara-Corrales et al study using a dose of 2000 IU/day for 3 months did not significantly improve AD severity.

4. Meta-analysis studies show that statistically vitamin D supplementation when compared with placebo improves the severity but not cure rate of atopic dermatitis.

5. The conclusion can be added regarding the results of the meta-analysis related to the risk ratio although the results are not statistically significant.

6. In the discussion section, it can be discussed more deeply about the literature included in the study other than the facts that are generally known.

Are the rationale for, and objectives of, the Systematic Review clearly stated?
Yes

Are sufficient details of the methods and analysis provided to allow replication by others?
Yes

Is the statistical analysis and its interpretation appropriate?
Yes

Are the conclusions drawn adequately supported by the results presented in the review?
Partly

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Dermatology and Venereology, Allergy and Immunology, Dermatosis occupational.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 26 May 2023

Afif Nurul Hidayati

Dear Dr. Budianti,

Firstly, we would like to thank you for having our manuscript reviewed thoroughly, and for the helpful advice.

Based on our study, there were limitations of the data we used. Some of our literatures did not measure the level of Vitamin D in their subjects. Therefore, there was some studies showing improvement and otherwise did not show any significant improvement.

For the conclusion sections, to our knowledge, the supplementation of Vitamin D in atopic dermatitis patients is one of therapy that offer improvement in disease severity in despite of the doses and duration.

Thank you for the suggestions in your review

Best regards,

Afif Nurul Hidayati

**Competing Interests:** I disclosure there are NO any competing interests that might be construed to influence my judgement of this articles or peer review report's vaidity or importance.

Reviewer Report 21 March 2022

https://doi.org/10.5256/f1000research.117964.r126213

© 2022 Mawardi P. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Prasetyadi Mawardi
Department of Dermatology and Venereology, Faculty of Medicine, Dr. Moewardi General Hospital, Sebelas Maret University, Surakarta, Indonesia

This study provides optimal knowledge about the administration of vitamin D supplementation in children with atopic dermatitis. In this study, the results of a meta-analysis of 4 data included in the inclusion criteria had differences in the duration of vitamin D supplementation. Two data were given within a 3 month period, two data were provided within a 1 month period.

How do authors present their arguments? Although this has become part of the limitations of the study, it is not explained much in the discussion. Can researchers provide appropriate advice on dosing and duration of treatment with vitamin D supplementation? Vitamin D supplementation in children remains to be understood as an adjuvant therapy. The absence of an adequate dose of vitamin D supplementation should be a consideration for clinicians. It is known that in atopic dermatitis there is a filagrin mutation that causes the stratum corneum barrier system to not function properly and there is a second defect in tight junction abnormalities. Even though we know that an excessive increase in vitamin D levels will have a negative impact on the function of filagrin as the main barrier in patients with atopic dermatitis.

Are the rationale for, and objectives of, the Systematic Review clearly stated? Yes
Are sufficient details of the methods and analysis provided to allow replication by others? Yes
Is the statistical analysis and its interpretation appropriate? Yes
Are the conclusions drawn adequately supported by the results presented in the review? Yes

Competing Interests: No competing interests were disclosed.
Reviewer Expertise: dermatology and venereology

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response 28 Mar 2022
Afif Nurul Hidayati
Dear Dr. Mawardi,

We would like to firstly express our gratitude for having our manuscript reviewed thoroughly, and we would like to thank you for the helpful advice.
Currently, there is no guideline for recommended dose and duration of vitamin D administration that can be given to patients. However, in several studies, it is stated that patients with AD have low serum vitamin D levels, so some doctors use the dosage recommendations from the AAP (American Association of Pediatrics) and several health organizations.

In children aged 0-6 months, the maintenance dose for vitamin D administration is 400 IU with an upper limit of 2000 IU/day if including patients at risk of vitamin D deficiency. The largest group of children aged 11-18 years is recommended to give a dose of vitamin D 400 IU by the AAP and 600-1000 IU by the Endocrine society and 4000 IU at the upper limit dose. Therapeutic doses in patients with vitamin D deficiency or insufficiency range from 1000 IU to more than 5000 IU per day, according to age group.

**Competing Interests:** No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com